Acrivon-Aqilion Deal Announced on Nov. 6 Could Not Be Verified
Key Facts
The announcement on Nov. 6 that Acrivon had acquired drug assets from Aqilion could not be verified, so the completion of the deal and its terms cannot be confirmed. Aqilion had said in an earlier disclosure that talks to sell its projects for cash were non-binding and that there was no certainty an agreement would be reached. It also said due diligence preceded potential contractual negotiations concerning AQ128, AQ280 and PKCtheta. That disclosure framed the talks as an exploration of options to develop the projects, rather than an announcement of a completed deal. The information that could be verified did not confirm that the assets had transferred to Acrivon or specify the terms of any such transfer.
Aqilion said it held parallel talks during 2026 with potential partners to ensure the continued development of projects in its portfolio, whether through a partnership or a sale. In a disclosure issued on Aug. 28, it said it had received an indicative offer to buy all of the company's shares, but clarified at the time that no final offer had been presented to shareholders. The company linked any potential deal to the completion of due diligence. Alongside the company-sale process, it said it continued to explore licensing AQ280 and AQ128. This shows that partnership, licensing and asset-sale options were being considered through separate tracks in its earlier disclosures.
Aqilion says its business focuses on developing treatments for diseases caused by chronic inflammation and impaired immune responses, including autoimmune diseases. In an earlier update, it said both Phase 1 studies of AQ280 had been completed and that the results enabled the project to advance to Phase 2. It described the project as a highly selective oral JAK1 inhibitor and added that it had developed a water-soluble tablet to address swallowing difficulties among patients with eosinophilic esophagitis. Aqilion described AQ128 as a potent selective TAK1 inhibitor in development as a potential topical treatment for psoriasis. It said the project showed efficacy comparable to clobetasol in a psoriasis-like model, without the systemic effects observed with the comparator drug.
In the same update, Aqilion said it had discontinued the AQ312 project and put the PKCtheta project, which was at the early discovery stage, on hold to direct resources toward programs it considered more likely to reach value-generating milestones. Its disclosure of due diligence and potential negotiations concerning AQ128, AQ280 and PKCtheta had indicated the scope of projects under discussion, but did not establish that they had been sold. The information that could be verified did not include a disclosure clarifying whether the non-binding sale talks had resulted in an agreement with Acrivon. No confirmed details are available on the consideration, deal terms or completion date. These details remain unresolved in the documented information available.